Press release
Gossamer Bio Announces Second Quarter 2020 Financial Results and Provides Corporate Update
- GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 - -
About this update from Gossamer Bio, Inc.
[{"type":"text","content":"\n- GB001: Phase 2 studies, LEDA in eosinophilic asthma and TITAN in chronic rhinosinusitis, on track for topline data readout in the second half of 2020 -\n\n\n- GB002: Expected to commence Phase 2 TORREY study in pulmonary arterial hypertension in the second half of 2020 -\n\n\n- GB004: Expected to commence Phase 2 SHIFT-UC study in ulcerative colitis in the second half of 2020 -\n\n\n- Cash, cash equivalents and marketable securities totaled $600 million as of June 30, 2020 -\n\n SAN DIEGO--(BUSINESS WIRE)--\nGossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing and commercializing therapeutics in the disease areas of immunology, inflammation and oncology, today announced its financial results for the second quarter 2020 and provided a corporate update.\n\n\n“I hold tremendous pride in the progress made by the Gossamer team to date,” said Sheila Gujrathi, M.D., Co-Founder and Chief Executive Officer of Gossamer. “We look forward to the continued advancement of our product candidates, and before year end, we are excited for the achievement of milestones across all four of our clinical programs.”\n\n\nClinical-Stage Product Candidate Updates\n\n\nGB001: Oral DP2 Antagonist for Eosinophilic Asthma and Chronic Rhinosinusitis (CRS)\n\n\n\nPhase 2b LEDA study in patients with moderate-to-severe eosinophilic asthma is on track to report topline data in the second half 2020.\n\n\nPhase 2 TITAN study in patients with chronic rhinosinusitis, both with and without nasal polyps, is also on track to report topline data in the second half 2020.\n\n\n\nGB002: Inhaled PDGFR Inhibitor for Pulmonary Arterial Hypertension (PAH)\n\n\n\nGB002 is currently being evaluated in an ongoing Phase 1b study in PAH. Given COVID-19 related delays in study enrollment, Gossamer anticipates reporting initial results from this study in the second half of this year.\n\n\nSubject to developments in the ongoing COVID-19 pandemic, Gossamer plans to commence TORREY, a Phase 2 study in functional class II and III PAH patients in the second half of 2020. The primary endpoint for this 24-week study will be change in pulmonary vascular resistance (PVR) from baseline. The key secondary endpoint will be change from baseline in 6-minute walk distance at week 24.\n\n\n\nGB004: Oral HIF-1α Stabilizer for ...